Evidence map›Paper›PMID 40883321›Full record

ArticleNature communications2025

GD2T

Guangyue Zhang, Na Yin, Min Peng

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guangyue ZhangState Key Laboratory of Molecular Oncology, Tsinghua University, Beijing, China.ORCID http://orcid.org/0000-0003-4051-8616
Na YinState Key Laboratory of Molecular Oncology, Tsinghua University, Beijing, China.ORCID http://orcid.org/0000-0002-8280-6512
Min PengState Key Laboratory of Molecular Oncology, Tsinghua University, Beijing, China. pengmin@tsinghua.edu.cn.ORCID http://orcid.org/0000-0002-5885-0660

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82350108Tsinghua University (THU) 52302102323
6 · The paper itself

Abstract

The efficacy of biologics, such as peptide and protein drugs, is often limited by their short half-lives in vivo, necessitating repeated infusions to maintain therapeutic effects. Here, we demonstrate that long-lived CAR T cells can be leveraged as a versatile platform for long-term delivery of biologics. Our recent findings show that the depletion of BCOR and ZC3H12A induces GD2 CAR T cells into an immortal-like and functional state, which we have termed GD2T

Indexed as

Biological ProductsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsDiet, High-FatFemaleGlucagon-Like Peptide 1HumansLeptinMaleMiceMice, Inbred C57BLObesityBiological ProductsGlucagon-Like Peptide 1LeptinReceptors, Chimeric Antigen

Identifiers

PMID40883321
PMCPMC12397235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.